Immuron Ltd (IMC)

Currency in AUD
0.063
-0.001(-1.56%)
Closed·
IMC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IMC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0630.063
52 wk Range
0.0540.110
Key Statistics
Bid/Ask
0.064 / 0.075
Prev. Close
0.064
Open
0.063
Day's Range
0.063-0.063
52 wk Range
0.054-0.11
Volume
6.2K
Average Volume (3m)
169.09K
1-Year Change
-42.73%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Immuron Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Immuron Ltd Company Profile

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers’ diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Employees
7
Market
Australia

Compare IMC to Peers and Sector

Metrics to compare
IMC
Peers
Sector
Relationship
P/E Ratio
−2.3x−4.0x−0.5x
PEG Ratio
0.03−0.040.00
Price/Book
1.7x3.0x2.6x
Price / LTM Sales
2.6x20.1x3.2x
Upside (Analyst Target)
-279.3%43.8%
Fair Value Upside
Unlock−6.7%8.1%Unlock

Earnings

Latest Release
May 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMC Income Statement

FAQ

What Stock Exchange Does Immuron Ltd Trade On?

Immuron Ltd is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Immuron Ltd?

The stock symbol for Immuron Ltd is "IMC."

What Is the Immuron Ltd Market Cap?

As of today, Immuron Ltd market cap is 16.90M.

What Is Immuron Ltd's Earnings Per Share (TTM)?

The Immuron Ltd EPS (TTM) is -0.03.

When Is the Next Immuron Ltd Earnings Date?

Immuron Ltd will release its next earnings report on 28 Aug 2025.

From a Technical Analysis Perspective, Is IMC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Immuron Ltd Stock Split?

Immuron Ltd has split 5 times.

How Many Employees Does Immuron Ltd Have?

Immuron Ltd has 7 employees.

What is the current trading status of Immuron Ltd (IMC)?

As of 01 Aug 2025, Immuron Ltd (IMC) is trading at a price of 0.06, with a previous close of 0.06. The stock has fluctuated within a day range of 0.06 to 0.06, while its 52-week range spans from 0.05 to 0.11.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.